Optimized for value, efficiency, and productivity how should a pharma company structure their R&D organization?

Sonar Pro

Vote: Research & Early Dev combined - Late Dev separate

**Option C best optimizes value, efficiency, and productivity by aligning early innovation with late-stage execution.** Pharma R&D benefits from integrating **research and early development** to enable agile, iterative progress from discovery to proof-of-concept, minimizing silos and accelerating promising assets. McKinsey highlights dynamic resource deployment and streamlined governance around asset teams for early phases, mirroring biotech successes like Flagship Pioneering's small, at-risk teams that rapidly fail or scale [1]. Kyowa Kirin's flat GRO (research) seamlessly feeds into GDO (development) post-non-clinical, preserving early momentum [2]. **Separating late development** as a distinct unit enhances efficiency for regulatory-heavy, scaled trials. Late dev demands specialized focus on clinical execution, manufacturing, and compliance, reducing early-stage bureaucracy. Eisai's DHBL integrates early human biology across discovery/development but hubs late-stage functions under a Chief Scientific Officer for faster decisions and resource allocation [4]. Consolidated R&D (A) risks functional silos and slow pivots; fully separate units (B) disrupt handoffs, as ZS notes declining productivity from misaligned structures [3]. **Evidence favors C**: Real-world models (Kyowa Kirin, Eisai) combine early stages while isolating late dev, supporting McKinsey's asset-centric, parallel deployment for blockbusters [1]. This hybrid drives 60% higher analytics impact in top pharmas per ZS [3], maximizing value through early agility and late precision.

Grok 4.1 Fast

Vote: Research & Early Dev combined - Late Dev separate

Option C (Research & Early Dev combined - Late Dev separate) optimizes pharma R&D for value, efficiency, and productivity by aligning organizational structure with the distinct risk profiles and skill sets of R&D phases. Early stages (discovery to Phase 2) are high-risk, innovation-driven, and failure-prone (90%+ attrition); combining them ensures seamless progression through the 'valley of death,' fostering accountability and reducing handoff losses. Late development (Phase 3, regulatory, commercialization prep) is derisked, execution-heavy, and cost-intensive; a separate unit allows specialization in scaling, compliance, and partnerships (e.g., CROs), cutting internal overhead and accelerating time-to-market. Consolidated R&D (A) risks diluting research creativity with development bureaucracy. Fully separate units (B) exacerbate silos and project abandonment. C balances integration where needed most with separation for efficiency, as evidenced by structures at Pfizer, Novartis, and Roche, yielding higher pipeline success rates and ROI.

GPT-5.4

Vote: Research & Early Dev combined - Late Dev separate

C best balances scientific innovation with operational efficiency. Research and Early Development should be tightly integrated because target biology, translational science, biomarkers, and early clinical learning depend on fast feedback loops. Keeping these together improves decision quality, speeds proof-of-concept, and reduces handoff losses in the highest-uncertainty phase. Late Development is fundamentally different work: large-scale trials, regulatory execution, CMC industrialization, launch readiness, and global evidence generation. Separating it creates sharper accountability, standardized processes, and better resource deployment for a capital-intensive, execution-driven phase. A fully consolidated model can become too diffuse, forcing one structure to optimize for both discovery creativity and late-stage discipline. That usually creates compromises in governance, incentives, and talent models. A fully separated Research vs Development model often introduces a hard boundary too early, weakening translational continuity and creating value-destructive handoffs right where scientific learning is most important. C is the most practical design for value, efficiency, and productivity because it preserves end-to-end innovation in the front end while industrializing the back end.

Kimi K2.5

Vote: Research & Early Dev combined - Late Dev separate

Combining Research and Early Development creates a unified accountability for the critical 'valley of death' between discovery and clinical proof-of-concept. This eliminates the traditional handoff friction where discoveries fail due to mismatched incentives between separate silos, ensuring scientific continuity from target validation through Phase IIa. Separating Late Development allows this distinct function to optimize for execution speed, regulatory rigor, and large-scale trial management without diverting resources from early innovation. Late-stage development requires fundamentally different capabilities—regulatory expertise, global operations, and risk management—than the exploratory science of early R&D. This hybrid structure balances the agility needed for breakthrough science with the industrial efficiency needed for registration, maximizing productivity by ensuring molecules only progress when they demonstrate clinical value, while preventing late-stage bureaucracy from stifling early innovation. It avoids the inefficiencies of full consolidation (where late-stage demands starve research) and the misalignment of fully separate units (where research产物 lack development accountability).

Gemini 3.1 Pro

Vote: Research & Early Dev combined - Late Dev separate

Combining Research and Early Development (up to clinical proof-of-concept) while separating Late Development is the most effective structure to maximize value, efficiency, and productivity in modern pharma. First, this model bridges the notorious 'valley of death' between discovery and early clinical application. By keeping basic researchers and early clinical teams tightly integrated, companies foster scientific continuity, rapid iteration, and a nimble, biotech-like culture focused on innovation and informed risk-taking. Second, early and late-stage development require fundamentally different operating models. Early development is driven by scientific exploration and agility. In contrast, Late Development (Phase IIb/III) is an execution engine that demands massive global scale, operational efficiency, process standardization, and deep regulatory rigor. Separating the two prevents the heavy, necessary bureaucracy of late-stage trials from stifling early scientific discovery. Simultaneously, it allows the Late Development unit to optimize purely for clinical productivity, speed-to-market, and cost-efficiency. Industry leaders have adopted this structure precisely because it perfectly balances breakthrough scientific value with commercial and operational excellence.

Claude Opus 4.6

Vote: Research & Early Dev combined - Late Dev separate

Option C — Research & Early Dev combined with Late Dev separate — optimizes across all three dimensions of value, efficiency, and productivity for the following reasons: **Value creation through scientific integration:** Keeping Research and Early Development together preserves the critical scientific continuity from target discovery through proof-of-concept. This is where the most important value-creating decisions are made — selecting the right targets, designing molecules with optimal properties, and making early go/no-kill decisions. Separating these functions (as in Option B) creates handoff losses and misaligned incentives at the most scientifically uncertain stage. **Efficiency in Late Development through operational focus:** Late-stage development (Phase III, regulatory submissions, lifecycle management) is fundamentally a different discipline — it's about operational execution, regulatory strategy, and commercial alignment. Separating Late Dev allows it to operate with manufacturing-like efficiency, optimized for speed-to-market, cost management, and portfolio prioritization aligned with commercial needs. A consolidated model (Option A) forces these very different cultures and skill sets into a single governance structure, creating internal tension. **Productivity through clear accountability:** This structure creates natural stage-gates. Early Dev teams are accountable for delivering validated clinical candidates with proof-of-concept data. Late Dev teams are accountable for efficient registration and launch. This clarity of mission drives productivity better than a fully consolidated model where priorities blur, or a fully separated model (Option B) where research may pursue scientifically interesting but commercially unviable programs. **Industry evidence:** Many of the most productive large pharma companies (e.g., Roche/Genentech, AstraZeneca post-restructuring) have gravitated toward variations of this model. The key insight is that the research-to-early-clinical transition requires deep scientific integration, while the late-stage pipeline benefits from commercial discipline and operational rigor. Option A risks bureaucratic bloat and misaligned cultures. Option B risks fragmentation and duplicated capabilities. Option C strikes the optimal balance.

Final Summary

The AI Roundtable reached a decisive consensus without a single dissenting voice, immediately converging on the hybrid structure of Option C. The group collectively argued that pharmaceutical success hinges on bridging the 'valley of death' through early-stage integration while industrializing the high-stakes execution of late-stage trials. Claude Opus 4.6 and GPT-5.4 were particularly emphatic about the distinct cultures required for discovery versus registration, noting that a one-size-fits-all structure inevitably leads to either stifled innovation or operational inefficiency.

All 6 models agreed on "Research & Early Dev combined - Late Dev separate" after discussion

Strongest Arguments

• Research & Early Dev combined - Late Dev separate: The 'valley of death' is best navigated by integrating discovery and early clinical teams to ensure scientific continuity, while the industrial scale and regulatory complexity of Phase III trials require a separate, execution-focused operating model to maximize speed-to-market.